COMP <GO>
CSTL vs ABBV // DIVIDEND YIELD & FCF PAYOUT SAFETY
Castle Biosciences Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CSTL 2
— ABBV 9
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: ABBV
LAST: $38.51 (+4.99%) • MKT CAP: $1.18B
dividend-safety
0.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
dividend-safety
2.27%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CSTL VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CSTL | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.40% | 70.20% | +9.20 | CSTL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -9.30% | 29.00% | -38.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.41% | 3.47% | -1.06 | ABBV | /fcf-yield <GO> |
| Operating Margin | -12.40% | 24.60% | -37.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 6.90% | -13.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 3.70% | 8.60% | -4.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.97 | 5.33 | +1.64 | CSTL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.9 | 65.1 | -4.23 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.18B | $513.86B | -$512.68B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CSTL REV | ABBV REV | CSTL GROSS % | ABBV GROSS % | CSTL FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $344.2M | $61.16B | 79.4% | 70.2% | $28.3M | $17.82B |
| FY 2024 | $332.1M | $56.33B | 81.9% | 70.0% | $36.5M | $17.83B |
| FY 2023 | $219.8M | $54.32B | — | — | -$5.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CSTL // BETA —
ABBV // BETA 1.15